Germany-based NVision Raises $55M In Series B Funding Led By Abbott

The financing also included a $17 million venture loan from the European Investment Bank (EIB), bringing NVision’s total funding to $120 million.

The company plans to use the new capital to expand operations and accelerate development efforts.

Founded in 2015 and led by CEO Sella Brosh, NVision develops quantum technologies for healthcare, specializing in engineering and controlling the quantum properties of organic molecules.

Its POLARIS platform enables real-time metabolic imaging on standard MRI systems, helping researchers evaluate treatment responses within hours or days instead of months.

Alongside its imaging technology, NVision announced a major expansion into quantum computing through its Photonic Integrated Quantum Circuits (PIQC) platform.

Read Also - MovitOn Acquires Glocalzone To Grow Decentralised Logistics Network

The company recently discovered a new class of organic molecule-based qubits, which are being integrated onto photonic chips to create scalable quantum computing systems using standard semiconductor manufacturing methods.

NVision aims to combine quantum computing for drug design with quantum-enhanced MRI for rapid real-world validation, creating an end-to-end “compute and validate” approach for therapy development.

POLARIS systems are already being deployed at leading cancer centers, including Memorial Sloan Kettering Cancer Center, the University of Cambridge, and the Technical University of Munich, with around 20 installations expected across the U.S., Europe, and Asia by the end of the year.

“I see a future where quantum computers generate an explosion of drug hypotheses for diseases that are exceptionally difficult to treat today,” said Sella Brosh, CEO and Co-Founder of NVision. “As we expand our ambition into quantum computing, building on our remarkable new class of organic molecule-based qubits, that future comes closer. But without translational speed, we won’t fully realize those gains. POLARIS is built exactly to address this, enabling rapid in-vivo validation and closing the loop between design and reality.”

About NVision Quantum

NVision Quantum develops advanced imaging technology that makes MRI scans more detailed and effective. Its POLARIS platform helps doctors and researchers detect diseases earlier evaluate treatments faster and better understand patient health across cancer heart, brain and other medical conditions.